FMD方案治疗惰性淋巴瘤的临床观察

 目的　分析FMD方案初治惰性淋巴瘤的疗效及毒副作用。方法　24例确诊惰性淋巴瘤患者初治采用FMD方案：氟达拉滨（Flu）25～30 mg·m-2·d-1，静脉滴注30 min，第1天至第3天；米托蒽醌（Mit）10 mg·m-2·d-1，静脉滴注30 min，第1天；地塞米松（Dxm）40 mg／d，静脉滴注，第1天至第5天。结果　24例患者中，完全缓解（CR）54.1 ％，部分缓解（PR）29.1 ％，有效率为83.2 ％。主要毒副作用是骨髓抑制。结论　FMD方案初治惰性淋巴瘤临床效果好，患者可以耐受，是一种安全有效的较理想的方案

Clinical observation of first treating indolent non-Hodgkin lymphoma by FMD regimen

Objective　To discuss the therapeutic effect and toxicity of FMD regimen in initial un－treated patients with indolent non-Hodgkin lymphoma. Methods　24 initial untreated patients with indolent non-Hodgkin lymphoma were treated with FMD regimen : Fludarabine 25～30 mg/m2 intravenously(IV) for 30 minutes days 1～3, Mitoxantrone 10 mg/m2 IV for 30 minutes day1, Dexamethasone 40 mg IV days 1～5. Results　Of the 24 patients, complete response(CR) rates were 54.1 ％, partial response rates were 29.1 ％,overall response rates were 83.2 ％. The most common side effects were myelosuppression and immunosuppression. Conclusion　The FMD regimen is a well-effective and tolerated treatment regimen for initial untreated patients with indolent non-Hodgkin lymphoma.